Efficacy of immune checkpoint inhibition in patients with advanced NSCLC with KRAS, MET, other minor driver alterations

Yuji Uehara,Kageaki Watanabe,Taiki Hakozaki,Kie Mirokuji,Kana Hashimoto,Kosuke Narita,Shoko Kawai,Makiko Yomota,Yukio Hosomi

ANNALS OF ONCOLOGY（2022）

Cited 0|Views5

No score

Abstract

First-line Immune-checkpoint inhibitor (ICI) efficacy in patients with NSCLC harboring molecular alterations remains unclear. This study was undertaken to determine first-line ICI efficacy against KRAS-, MET-, BRAF-, HER2-, PIK3CA-, RET-, FGFR-NSCLC in a real-world setting.

Translated text

Key words

immune checkpoint inhibition,advanced nsclc

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined